Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerA systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancerChemotherapy- and irradiation-induced bone loss in adults with solid tumorsAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Letrozole induced hypercalcemia in a patient with breast cancer.Aromatase inhibitors-induced bone loss in early breast cancer.Increased fracture rate in women with breast cancer: a review of the hidden risk.Aromatase inhibitors in post-menopausal endometriosis.Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomicsFracture in asian women with breast cancer occurs at younger ageBreast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor.Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementCancer Treatment-Induced Bone Loss in women with breast cancerEarly operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancerAromatase inhibitors and calcium absorption in early stage breast cancer.Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.The management of osteoporosis in breast cancer survivors.Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Osteoporosis and cancerPreventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole.Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancerGenetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGSystematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.Inhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.Lumbar Scoliosis in Patients With Breast Cancer: Prevalence and Relationship With Breast Cancer Treatment, Age, Bone Mineral Density, and Body Mass Index.The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.Death causes in breast cancer patients.Cancer Treatment and Bone Health.Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
P2860
Q26746212-7A22BA4B-D21C-44F3-B6FA-5B07AC220418Q27008869-C45087A8-5C3F-48D3-AE04-AA83F0E5A820Q28084019-34489B44-2D45-4FBF-92CC-D52ADD0B5AD9Q33631047-C94A8AA2-9472-4B42-AF18-DC37CB9918F8Q33737423-31251F82-31C7-40D3-BAD3-ABC52D129C96Q33752867-161D346F-FC08-4F83-841A-E0EE7D4C2C95Q34004925-ACB4B95E-AFC1-4B5E-8E89-EA17854440C4Q34194386-F56B51F1-3EBB-4459-90B2-245F775AF0B9Q34265045-48C87F0E-CACA-41E2-9DD2-9C067B45DDF3Q34999480-CC5EA4FB-716C-47AE-AA48-A855445697AEQ35066907-C0C6DF27-0B76-4E3D-91FC-F15B55DD2165Q35095538-B50419B8-716A-4B48-8BE0-0660CF704550Q35490056-4B7A62B7-1322-442A-9B92-12D62B3DEFEDQ35557992-ABFABF59-4CBD-4BAC-B795-38F6C8DD4399Q35558893-53689DF2-636D-424A-AC89-C3ECACAE27F9Q35632616-8436D6AA-97A8-4BAE-9933-4081CFA50EE7Q35653956-8A829F94-3EAC-46EF-B30B-E349BF86A6FDQ35802184-EAB6B5FA-A8CB-433A-8CE0-28F9569E89E5Q36037270-30C43283-01A9-40CC-A9A3-54CC0B13FC39Q36278395-1FBF6680-5BBE-4F34-9BFF-6183149EC37CQ36405775-030E29AB-2A7B-4165-9399-A66854C24CE0Q36728379-A8B064B1-CB14-46ED-B732-E0E05F26269FQ37135281-AD661041-4E36-46DC-9495-E24194313358Q37198504-5B3C0668-06EA-4BBC-91BE-8E0B090AB8FFQ37338100-D1976B9E-C5A8-4F3C-B64C-71014CAA892EQ37350988-EAEAC9A3-1871-4686-B753-E9F90DCE47A7Q37356084-95032D3A-E8D4-4470-A09E-F8C566D7B4ACQ37665513-ECEDFCB9-430D-49AB-B847-A205F07BD2DDQ37696677-4FBBF038-7C60-4CA6-8315-36EACFAD1D64Q37699857-837AD000-7DA5-40ED-B8FE-5B9A7A05A748Q37742180-00FDC03F-FBB8-4CC6-A7E4-79B7C16999EDQ38044039-8425A60B-A6EC-4B5B-B79E-EEFE0A5D0CEAQ38553766-0CC393D9-DFE1-4D53-A171-0E3FF7F930E6Q41442004-9D996536-36D8-4731-95BA-7C1C2CD11DDBQ43567721-7F0A1AD2-A261-494D-83DE-A638CE67431CQ46735572-1ED08759-AF20-43A2-AF03-EFE06A4B1267Q47424252-F20456B4-316B-4111-8F18-91DC1BE774C3Q48869594-8392B8D8-0CCF-4BEC-833F-3AE252F5336FQ49211720-48D6A151-F1BE-4904-8493-70F753D9C68DQ53136867-BC3BF123-9B57-42E3-8AC7-B2FB609AD0B4
P2860
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@en
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@nl
type
label
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@en
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@nl
prefLabel
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@en
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@nl
P2093
P2860
P356
P1433
P1476
Bone fractures among postmenop ...... moxifen in the BIG 1-98 trial.
@en
P2093
A Goldhirsch
A S Coates
B Thürlimann
BIG 1-98 Collaborative and International Breast Cancer Study Groups
H Mouridsen
J F Forbes
J-M Nogaret
P2860
P304
P356
10.1093/ANNONC/MDP033
P577
2009-05-27T00:00:00Z